Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 studyLUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP
Arcturus showed their medicine was safe and worked on important health markers. This hints the company is making progress, so watch if future tests stay strong.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.